What one analyst described as Heron Therapeutics Inc.'s "profound benefit" in phase II data with HTX-011 for post-bunionectomy pain triggered speculation about how the findings might translate into a pivotal trial with the compound, a long-acting formulation of the numbing agent bupivacaine in a fixed-dose pairing with the anti-inflammatory therapy meloxicam.